Decapeptyl triptorelin pamoate: Additional Phase III data

Additional data from a single-arm, open-label, European Phase III trial in patients with locally advanced or metastatic prostate cancer showed that a 3-month formulation of 11.25 mg subcutaneous Decapeptyl led to castration in 97.6% of men

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE